When prescribed to women with estrogen receptor (ER)-positive early breast cancer for 5–10 years, it reduced the risk of breast cancer recurrence, reduced breast cancer mortality, and reduced overall mortality [228]. This evidence concerns the gene ESR1 and breast carcinoma.